GlobeImmune (GBIM) Given Daily Media Impact Rating of 0.34
News headlines about GlobeImmune (NASDAQ:GBIM) have been trending positive on Sunday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. GlobeImmune earned a media sentiment score of 0.34 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 44.6469525887737 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of GlobeImmune (NASDAQ GBIM) traded down 0.50% on Friday, reaching $0.52. 7,424 shares of the company’s stock traded hands. The firm’s 50 day moving average is $0.60 and its 200 day moving average is $0.44. GlobeImmune has a 52 week low of $0.11 and a 52 week high of $1.76. The firm’s market capitalization is $2.99 million.
COPYRIGHT VIOLATION WARNING: “GlobeImmune (GBIM) Given Daily Media Impact Rating of 0.34” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://theolympiareport.com/2017/10/08/globeimmune-gbim-given-daily-media-impact-rating-of-0-34.html.
GlobeImmune, Inc is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s segment is the business of developing and commercializing various biopharmaceutical products. The Company’s infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection.
Receive News & Ratings for GlobeImmune Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlobeImmune Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.